BioSpecifics Technologies Corp. to Report Fourth Quarter and Full Year 2015 Financial Results on Monday, March 14, 2016

Mar 07, 2016, 08:00 ET from BioSpecifics Technologies Corp.

LYNBROOK, N.Y., March 7, 2016 /PRNewswire/ -- BioSpecifics Technologies Corp. (NASDAQ: BSTC), a biopharmaceutical company that originated and continues to develop collagenase-based therapies with a first in class collagenase-based product marketed as XIAFLEX® (collagenase clostridium histolyticum or CCH) in the U.S. and Xiapex® in Europe, announced today that it will host a conference call and live audio webcast at 8:30 a.m. ET on Monday, March 14, 2016 to report its fourth quarter and full year 2015 financial results and to provide a corporate update.

In order to participate in the conference call, please dial 1-866-364-3867 (domestic) or 1-412-902-4213 (international). The live webcast can be accessed under "Events and Presentation" in the "Investors" section of the Company's website at www.biospecifics.com or you may use the link: https://www.webcaster4.com/Webcast/Page/967/13218.

A replay of the call will be available one hour after the end of the conference on March 14, 2016 until 8:30 a.m. ET on March 21, 2016. To access the replay, please dial 1-877-344-7529 (domestic) or 1-412-317-0088 (international) and reference the access code 10080981. The archived webcast will be available for ninety days in the Investors section of BioSpecifics' website at www.biospecifics.com.

About BioSpecifics Technologies Corp.

BioSpecifics Technologies Corp. is a biopharmaceutical company that has developed injectable collagenase for twelve clinical indications to date. Injectable collagenase is marketed as XIAFLEX® in the U.S. for the treatment of Dupuytren's contracture and Peyronie's disease by BioSpecifics' partner, Endo International plc (Endo). XIAFLEX® is also commercialized in Japan, the E.U., Canada and Australia for Dupuytren's contracture and in the E.U. and Switzerland for Peyronie's disease. Endo has the following partnerships outside the U.S. for these two indications; Swedish Orphan Biovitrum AB has marketing rights for Xiapex® (the EU tradename) in 71 Eurasian and African countries, Actelion Pharmaceuticals Ltd. has marketing rights in Canada and Australia and Asahi Kasei Pharma Corporation has marketing rights in Japan. The XIAFLEX development pipeline includes several additional promising indications. Endo is managing development of cellulite, adhesive capsulitis, canine lipoma, lateral hip fat and plantar fibromatosis. BioSpecifics is managing the clinical development of human lipoma and plans to initiate clinical development of uterine fibroids in the second half of 2016. For more information, please visit www.biospecifics.com.

SOURCE BioSpecifics Technologies Corp.



RELATED LINKS

http://www.biospecifics.com